Gyre Therapeutics
GYRE
39 hedge funds and large institutions have $22.9M invested in Gyre Therapeutics in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 12 closing their positions.
192% more call options, than puts
Call options by funds: $155K | Put options by funds: $53K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
15% less funds holding
Funds holding: 46 → 39 (-7)
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
69% less capital invested
Capital invested by funds: $72.8M → $22.9M (-$49.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWM
Essex Woodlands Management
The Woodlands,
Texas
|
+$16M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$950K |
| 3 |
Goldman Sachs
New York
|
+$720K |
| 4 |
DCM
DG Capital Management
New York
|
+$363K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$319K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$1.71M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$567K |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$441K |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$406K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$206K |
GYRE Hedge Fund Activity: Q3 2015 in Review
39 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2015, worth a combined $22.9M — down 69% from $72.8M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of GYRE and 5 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 11 added.
The largest buyer was Essex Woodlands Management, opening a new position worth an estimated $16M. The largest seller was Franklin Resources, exiting entirely with an estimated $1.71M sold.
- 39 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2015, down from 46 in Q2 2015.
- Funds reported $22.9M of Gyre Therapeutics stock for Q3 2015, down 69% quarter-over-quarter.
- 5 funds opened new Gyre Therapeutics positions in Q3 2015 and 12 closed out, a net change of -7 holders.
- The largest Gyre Therapeutics buyer in Q3 2015 was Essex Woodlands Management, an estimated $16M added.
- The largest Gyre Therapeutics seller in Q3 2015 was Franklin Resources, an estimated $1.71M sold.
Based on aggregated 13F filings for Q3 2015.